Drug Trial Radar · NCT00647530
Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery
Last checked: Nov 19, 2026Latest source record: May 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,053
Actual
Start
May 15, 2008
Primary completion
Dec 23, 2016
Study completion Dec 31, 2019
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective with or without panitumumab in treating patients with colon cancer. PURPOSE: This randomized phase III trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high risk operable colon cancer.
Conditions
- Colorectal Cancer
Interventions
panitumumabBiological
capecitabineDrug
fluorouracilDrug
oxaliplatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from recurrence or persistent disease (including failure of macroscopic disease clearance at primary surgery) within the first two years following randomizationTime frame: 2 year post randomization
- Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumabTime frame: Time of surgery
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Birmingham Clinical Trials Unit
Birmingham, England, United Kingdom
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
Birmingham, England, United Kingdom
Queen Elizabeth Hospital
Gateshead, England, United Kingdom
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, United Kingdom
Royal Lancaster Infirmary
Lancaster, England, United Kingdom
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom
Clatterbridge Centre for Oncology
Metropolitan Borough of Wirral, England, United Kingdom
Derriford Hospital
Plymouth, England, United Kingdom
Southport and Formby District General Hospital
Southport, England, United Kingdom
Sandwell General Hospital
West Bromwich, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.